Compare L3Harris Technologies Inc (LHX) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Nuvalent Inc — how do they compare? L3Harris Technologies Inc trades at $279.42 (market cap $52.27B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: L3Harris Technologies Inc is far larger — about 5.3× Nuvalent Inc's market cap, and L3Harris Technologies Inc pays a 1.78% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| LHX | NUVL | |
|---|---|---|
Market Cap | $52.27B | $9.81B |
Sector | Industrials | Technology |
52-Week High | $378.48 | $123.96 |
52-Week Low | $263.09 | $72.16 |
Enterprise Value | $63.03B | $8.52B |
Dividend Yield | 1.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $280.57, down 0.51% today, with a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $2.72, beating estimates, and maintains robust cash flow. Recent contracts include a U.S. Space Force satellite deal and U.S. Army radio orders, supporting growth. Valuation metrics show a P/E of 30.62 and P/S of 2.36, with revenue rising to $21.87B in 2025.
Outlook is positive with a consensus price target of $367.50, implying 31% upside, driven by defense spending and execution. Risks include debt levels and geopolitical volatility. Analysts are 75% buy-rated, but technical indicators suggest near-term caution amid bearish moving averages.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.
The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
